ArticleCell2022
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 6 syntheses or guidelines pooled it, 287 citations in OpenAlex.
- Dietary interventions and the gut microbiota: a systematic literature review of 80 controlled clinical trials.Journal of translational medicine · 2026Pooled it
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types.Microbiology spectrum · 2025Pooled it
- Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Meta-analysis of the human gut microbiome uncovers shared and distinct microbial signatures between diseases.mSystems · 2024Pooled it
- Meta-analysis identifies common gut microbiota associated with multiple sclerosis.Genome medicine · 2024Pooled it
- Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Trial
- A randomized cross-over trial of prebiotics and probiotics in multiple sclerosis: Trial feasibility, supplement tolerability and symptom abatement.Multiple sclerosis and related disorders · 2024Trial
- Impact of dance classes on motor and cognitive functions and gut microbiota composition in multiple sclerosis patients: Randomized controlled trial.European journal of sport science · 2024Trial
- Gut microbiome and inflammation among athletes in wheelchair in a crossover randomized pilot trial of probiotic and prebiotic interventions.Scientific reports · 2024Trial
- Deconfounded, quantitative microbiome profiling identifies robust multiple sclerosis markers and clinical covariate associations.Gut microbes · 2026Article
- The Gut Microbiome in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Review
- Toward regionally equitable precision medicine: microbiota‑associated mechanisms and emerging personalized strategies in multiple sclerosis.Journal of translational medicine · 2026Review
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.mSystems · 2026Article
- CAR-T Cell Therapy and Gut Microbiota Modulation in Multiple Sclerosis: Emerging Therapeutic Strategies and Current Limitations.Current issues in molecular biology · 2026Review
- Proportionality-based association metrics in count compositional data.NAR genomics and bioinformatics · 2026Article
- A new paradigm of bidirectional regulation of the gut-spinal cord axis.Neural regeneration research · 2026Article
- Integrative multicohort analysis reveals consistent sex differences in gut microbiota of multiple sclerosis patients.mSystems · 2026Article
- Differential analysis of gut microbiota and metabolites in patients with Graves' disease and combined Helicobacter pylori infection.BMC endocrine disorders · 2026Article
- Azetidine-2-carboxylic acid-induced oligodendrogliopathy in vitro and the pathogenesis of multiple sclerosis.Journal of neuropathology and experimental neurology · 2026Article
138 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Changes in gut microbiota have been associated with several diseases. Here, the International Multiple Sclerosis Microbiome Study (iMSMS) studied the gut microbiome of 576 MS patients (36% untreated) and genetically unrelated household healthy controls (1,152 total subjects). We observed a significantly increased proportion of Akkermansia muciniphila, Ruthenibacterium lactatiformans, Hungatella hathewayi, and Eisenbergiella tayi and decreased Faecalibacterium prausnitzii and Blautia species. The phytate degradation pathway was over-represented in untreated MS, while pyruvate-producing carbohydrate metabolism pathways were significantly reduced. Microbiome composition, function, and derived metabolites also differed in response to disease-modifying treatments. The therapeutic activity of interferon-β may in part be associated with upregulation of short-chain fatty acid transporters. Distinct microbial networks were observed in untreated MS and healthy controls. These results strongly support specific gut microbiome associations with MS risk, course and progression, and functional changes in response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.